More recently, Flores-Gonzalez [70] reported on a MS patient on subcutaneous ofatumumab (approved in 2020 by the US Food and Drug Administration as once-monthly subcutaneous injection waiting approval by the EMA) who remained asymptomatic during SARS-CoV-2 infection and still developed neutralizing IgM and IgG antibodies three months after the infection, despite B-cell depletion. This evidence concerns the gene CD40LG and myeloid sarcoma.